Najah Albadari
Overview
Explore the profile of Najah Albadari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N, et al.
Genes Dis
. 2025 Jan;
12(2):101156.
PMID: 39802403
Targeting oncogenes and their interactive partners is an effective approach to developing novel targeted therapies for cancer and other chronic diseases. We and others have long suggested the MDM2 oncogene...
2.
Liu T, Gu L, Mui A, Wu Z, Albadari N, Li W, et al.
Cancer Lett
. 2024 Jul;
598:217126.
PMID: 39053726
The MDM2 oncogene is amplified and/or overexpressed in various human cancers and elevated expression of MDM2 protein acts as a survival factor promoting cancer progression through both p53-dependent and -independent...
3.
Wang W, Albadari N, Du Y, Fowler J, Sang H, Xian W, et al.
Pharmacol Rev
. 2024 May;
76(3):414-453.
PMID: 38697854
Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to the response...
4.
Lei Z, Albadari N, Teng Q, Rahman H, Wang J, Wu Z, et al.
Drug Resist Updat
. 2024 Feb;
73:101065.
PMID: 38367548
Aims: To investigate the collateral sensitivity (CS) of ABCB1-positive multidrug resistant (MDR) colorectal cancer cells to the survivin inhibitor MX106-4C and the mechanism. Methods: Biochemical assays (MTT, ATPase, drug accumulation/efflux,...
5.
Albadari N, Xie Y, Li W
Front Pharmacol
. 2024 Jan;
14:1340401.
PMID: 38269272
In 2023, colorectal cancer (CRC) is the third most diagnosed malignancy and the third leading cause of cancer death worldwide. At the time of the initial visit, 20% of patients...
6.
Albadari N, Xie Y, Liu T, Wang R, Gu L, Zhou M, et al.
Eur J Med Chem
. 2023 May;
255:115423.
PMID: 37130471
Overexpression of both human murine double minute 2 (MDM2) and X-linked inhibitor of apoptosis protein (XIAP) is detected in tumor cells from several cancer types, including childhood acute leukemia lymphoma...
7.
Albadari N, Li W
Molecules
. 2023 Feb;
28(3).
PMID: 36771042
Survivin, as a member of the inhibitor of apoptosis proteins (IAPs) family, acts as a suppressor of apoptosis and plays a central role in cell division. Survivin has been considered...
8.
Liu T, Gu L, Wu Z, Albadari N, Li W, Zhou M
Front Oncol
. 2022 Dec;
12:1058726.
PMID: 36505784
Amplification of the gene leads to its overexpression at both the mRNA and protein levels. Overexpression of mRNA may also have an important role in promoting neuroblastoma (NB) beyond the...
9.
Chen H, Deng S, Albadari N, Yun M, Zhang S, Li Y, et al.
J Med Chem
. 2021 Aug;
64(16):12049-12074.
PMID: 34378386
We previously reported a potent tubulin inhibitor CH-2-77. In this study, we optimized the structure of CH-2-77 by blocking metabolically labile sites and synthesized a series of CH-2-77 analogues. Two...
10.
Albadari N, Deng S, Chen H, Zhao G, Yue J, Zhang S, et al.
Eur J Med Chem
. 2021 Aug;
224:113719.
PMID: 34371464
The survivin (BIRC5) expression is very low in normal differentiated adult tissues, but it is one of the most widely upregulated genes in tumor cells. The overexpression of survivin in...